| Released | Contributor | Author | Title | Pages | Price |
|---|
| May 19, 2013 | New Constructs, LLC | N/A | EXEL: Due Diligence Review: Forensic Earnings and Valuation | 13 | $25 | | May 19, 2013 | Pechala's Reports | Lubomir Pechala | EXELIXIS INC (EXEL) - REPORT FOR ACTIVE TRADERS | 1 | $25 | | May 19, 2013 | Market Edge | N/A | Market Edge Equity Research Report | 4 | $10 | | May 19, 2013 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Medical-biomed/genetics | 18 | $207 | | May 17, 2013 | Pechala's Reports | Frantisek Pechala | EXELIXIS INC (EXEL) 12-months forecast | 1 | $15 | | May 16, 2013 | Ford Investor Services, Inc. | N/A | Industry Value Graph: EXEL , IMGN , MAXY , ONXX , VRNM -- DRUGS | 3 | $34.50 | | May 16, 2013 | Ford Investor Services, Inc. | N/A | Value Graph: EXELIXIS -- EXEL | 1 | $11.50 | | May 16, 2013 | Jefferson Research | N/A | Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of EXELIXIS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 11 | $20 | | May 15, 2013 | ValuEngine, Inc. | N/A | ValuEngine Detailed Valuation Report for EXEL | 11 | $126.50 | | May 12, 2013 | Alpha Street Research | Hunter Orr | EXEL - Exelixis Inc - Downgraded to a Sell - Company Analysis and ASR Ranking Report | 9 | $24 |
|
View All Reports for EXEL ... |
|
|
0.06(1.32%) 4:00PM EDT